Findings

What do systematic reviews say?

13 questions · 15 findings · 2 reviews · Lung Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 7 · 46.7%High 8 · 53.3%

Gefitinib vs chemotherapy alone

Overall survival (OS) · People with advanced non‐small cell lung cancer

Gefitinib showed no clear difference in overall survival (OS) compared with chemotherapy (moderate certainty).

2 findings from 1 review

Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
HR 0.98 [0.91, 1.46]
2 studies · 275 participants
Moderate
Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
HR 1.02 [0.91, 1.15]
2 studies · 1607 participants
Moderate

Gefitinib vs chemotherapy alone

Neutropenia · People with advanced non‐small cell lung cancer

Gefitinib leads to lower neutropenia compared with chemotherapy (high certainty).

1 finding from 1 review

Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
RR 0.04 [0.02, 0.06]
4 studies · 1857 participants
High

Gefitinib vs chemotherapy alone

Febrile neutropenia · People with advanced non‐small cell lung cancer

Gefitinib leads to lower febrile neutropenia compared with chemotherapy (high certainty).

1 finding from 1 review

Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
RR 0.12 [0.06, 0.23]
3 studies · 1768 participants
High

Gefitinib vs chemotherapy alone

Progression‐free survival · People with advanced non‐small cell lung cancer

Gefitinib showed no clear difference in progression‐free survival (PFS) compared with chemotherapy (moderate certainty).

2 findings from 1 review

Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
HR 1.19 [0.86, 1.65]
2 studies · 275 participants
Moderate
Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
HR 1.04 [0.92, 1.17]
2 studies · 1607 participants
Moderate

Gefitinib vs chemotherapy alone

Rash · People with advanced non‐small cell lung cancer

Gefitinib leads to higher skin rash compared with chemotherapy (high certainty).

1 finding from 1 review

Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
RR 2.4 [1.08, 5.31]
4 studies · 1858 participants
High

Gefitinib vs chemotherapy alone

Constipation · People with advanced non‐small cell lung cancer

Gefitinib leads to lower constipation compared with chemotherapy (high certainty).

1 finding from 1 review

Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
RR 0.41 [0.17, 0.97]
3 studies · 1719 participants
High

Gefitinib vs chemotherapy alone

Fatigue · People with advanced non‐small cell lung cancer

Gefitinib probably leads to lower fatigue compared with chemotherapy (moderate certainty).

1 finding from 1 review

Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
RR 0.16 [0.03, 0.88]
2 studies · 275 participants
Moderate

Gefitinib vs chemotherapy alone

Asthenia · People with advanced non‐small cell lung cancer

Gefitinib leads to lower asthenia compared with chemotherapy (high certainty).

1 finding from 1 review

Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
RR 0.51 [0.35, 0.75]
3 studies · 1773 participants
High

Gefitinib vs chemotherapy alone

Neurotoxicity · People with advanced non‐small cell lung cancer

Gefitinib leads to lower neurotoxicity compared with chemotherapy (high certainty).

1 finding from 1 review

Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
RR 0.07 [0.01, 0.34]
2 studies · 1529 participants
High

Gefitinib vs tri‐weekly paclitaxel plus carboplatin

Overall survival · EGFR M+ patients with NSCLC

Gefitinib showed no clear difference in overall survival compared with paclitaxel + carboplatin (high certainty).

1 finding from 1 review

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
HR 0.95 [0.77, 1.18]
2 studies · 489 participants
High

Gefitinib vs tri‐weekly paclitaxel plus carboplatin

Progression‐free survival · EGFR M+ patients with NSCLC

Gefitinib leads to lower progression‐free survival compared with paclitaxel + carboplatin (high certainty).

1 finding from 1 review

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
HR 0.39 [0.32, 0.48]
2 studies · 485 participants
High

Gefitinib vs pemetrexed + carboplatin with pemetrexed maintenance

Overall survival · EGFR M+ patients with NSCLC

Gefitinib showed no clear difference in overall survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).

1 finding from 1 review

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
HR 0.84 [0.63, 1.11]
2 studies · 371 participants
Moderate

Gefitinib vs pemetrexed + carboplatin with pemetrexed maintenance

Progression‐free survival · EGFR M+ patients with NSCLC

Gefitinib probably leads to lower progression‐free survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).

1 finding from 1 review

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
HR 0.59 [0.46, 0.74]
2 studies · 371 participants
Moderate